Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product, AVERSA FENTANYL. The meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine confirmed the regulatory pathway as a 505(b)(2) New Drug Application (NDA) and provided guidance on the reference listed drug and bridging strategy. This feedback marks a significant milestone for the company, as it clarifies the requirements for advancing AVERSA Fentanyl toward commercial approval.
The FDA also offered feedback on manufacturing validation, product specifications, and stability testing, along with expectations for in vitro manipulation and extraction studies to characterize AVERSA’s abuse-deterrent properties. These studies are critical to demonstrate that the patch can resist common methods of abuse, such as extraction of fentanyl for injection or inhalation. The agency’s input helps Nutriband design a robust development program that meets regulatory standards for abuse-deterrent opioid products.
The importance of this announcement lies in the potential of AVERSA Fentanyl to address the ongoing opioid crisis. Fentanyl is a potent synthetic opioid that is frequently abused, leading to thousands of overdose deaths annually. An abuse-deterrent formulation could reduce the risk of misuse, diversion, and accidental exposure, particularly among patients prescribed transdermal fentanyl for chronic pain. By incorporating AVERSA technology, the patch is designed to prevent common methods of abuse, thereby offering a safer alternative to existing fentanyl patches.
Nutriband’s AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company’s focus on abuse-deterrent formulations aligns with FDA priorities to encourage development of such products. The 505(b)(2) pathway allows Nutriband to rely on safety and efficacy data from previously approved drugs, potentially accelerating the approval process and reducing development costs.
The FDA’s guidance on the bridging strategy is particularly important, as it outlines how Nutriband can leverage data from a reference listed drug to support the NDA. This approach could streamline the clinical development plan, possibly avoiding the need for large-scale efficacy trials. Additionally, the agency’s feedback on manufacturing and stability testing ensures that Nutriband’s production processes meet quality standards required for commercial products.
Investors and stakeholders will be watching closely as Nutriband progresses toward NDA submission. The company’s newsroom at https://ibn.fm/NTRB provides updates on its developments. For more details on the FDA meeting feedback, the full press release is available at https://ibn.fm/RAzqc.
As Nutriband moves forward, the successful development of AVERSA Fentanyl could have significant public health implications by providing a safer pain management option and reducing the potential for opioid abuse. The company’s adherence to FDA guidance will be key to achieving this goal.
